PMVP sentiment intelligence

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Tone

Neutral 50/100

Event

Earnings

Published

13 Jul 2026 12:30

Source

Market source

ArrowMark Colorado Holdings (PMVP) holds 3.67% stake in PMV Pharmaceuticals

ArrowMark Colorado Holdings, LLC has reported a 3.67% beneficial ownership stake in PMV Pharmaceuticals, Inc., totaling 1,959,579 shares of common stock as of June 30, 2026. This filing, an amendment to Schedule 13G, indicates ArrowMark holds sole voting and dispositive power ove

Tone

Neutral 50/100

Event

Deals and strategy

Published

10 Jul 2026 15:41

Source

Stock Titan

PMV Pharmaceuticals outlines its cancer drug pipeline as shares trade quietly

PMV Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on precision oncology by targeting the p53 pathway in cancer. The company's pipeline revolves around developing therapies that modulate this key tumor suppressor mechanism, positioning it within the precisio

Tone

Neutral 50/100

Event

Market update

Published

07 Jul 2026 15:10

Source

AD HOC NEWS

PMV Pharmaceuticals holds the focus as investors await the next catalyst.

PMV Pharmaceuticals, an oncology company focused on p53 mutations, is attracting investor attention, with its stock performance heavily reliant on its clinical pipeline, financing, and trial readouts rather than a single event. The company's lead candidate, PMV-02, targets specif

Tone

Neutral 50/100

Event

Market update

Published

03 Jul 2026 18:40

Source

Ad-hoc-news.de

Price to earnings forward of PMV Pharmaceuticals, Inc. – NASDAQ:PMVP

This article provides the "Price to earnings forward" value for PMV Pharmaceuticals, Inc. (NASDAQ: PMVP). It's a quick data point for the company's financial overview, indicating a specific period, value, and change metrics. The article is hosted on TradingView, a financial chart

Tone

Neutral 50/100

Event

Earnings

Published

28 Jun 2026 18:10

Source

TradingView

Price to sales forward of PMV Pharmaceuticals, Inc. – NASDAQ:PMVP

This article displays the forward price-to-sales ratio for PMV Pharmaceuticals, Inc. (NASDAQ:PMVP). It is a financial data point presented by TradingView, indicating the company's valuation based on its future sales. The page also lists associated market data providers and copyri

Tone

Neutral 50/100

Event

Market update

Published

27 Jun 2026 05:40

Source

TradingView

PMV Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PMVP)

This article provides an overview of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) stock performance, financial actuals, and analyst estimates. It details the current stock price, market capitalization, earnings, and revenue, alongside historical highs and lows. The piece also includes

Tone

Neutral 50/100

Event

Earnings

Published

27 Jun 2026 03:10

Source

TradingView

Price to book forward of PMV Pharmaceuticals, Inc. – NASDAQ:PMVP

This article focuses on the "Price to book forward" financial metric for PMV Pharmaceuticals, Inc. (NASDAQ: PMVP). It appears to be a stub or a section within a larger financial data platform, providing a snapshot of this specific financial ratio without additional commentary or

Tone

Neutral 50/100

Event

Market update

Published

26 Jun 2026 21:10

Source

TradingView

Enterprise value to EBITDA forward of PMV Pharmaceuticals, Inc. – NASDAQ:PMVP

This article provides the enterprise value to EBITDA forward for PMV Pharmaceuticals, Inc. (NASDAQ:PMVP). It specifies that the market is currently closed with no trades, and the content is primarily a data point presented within the TradingView platform.

Tone

Neutral 50/100

Event

Market update

Published

25 Jun 2026 07:41

Source

TradingView

PMV Pharmaceuticals Inc (PMVP) Institutional Confidence

This article provides details on the institutional confidence in PMV Pharmaceuticals Inc (PMVP), as reflected by institutional shareholding data. It lists key institutional shareholders, their shareholdings, and changes in their positions. The data indicates varying levels of act

Tone

Neutral 50/100

Event

Market update

Published

18 Jun 2026 23:39

Source

TradingKey

PMV Pharmaceuticals Inc (PMVP) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for PMV Pharmaceuticals Inc (PMVP), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. It highlights that relevant data for these metrics have not yet been disclosed by the company. The article also includes current stock perfo

Tone

Neutral 50/100

Event

Market update

Published

18 Jun 2026 05:40

Source

TradingKey

PMV Pharmaceuticals Inc (PMVP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a detailed financial overview of PMV Pharmaceuticals Inc (PMVP). It highlights that relevant revenue breakdown data by business segment and region has not yet been disclosed by the company. The article includes current stock pricing, market c

Tone

Neutral 50/100

Event

Earnings

Published

17 Jun 2026 18:39

Source

TradingKey

PMV Pharmaceuticals Inc (PMVP) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of PMV Pharmaceuticals Inc (PMVP) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends in the past five years and shows no historical data for stock splits. The current stock price a

Tone

Neutral 50/100

Event

Capital return

Published

17 Jun 2026 18:39

Source

TradingKey

PMVP SEC Filings - Pmv Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms

This page provides a comprehensive overview of Pmv Pharmaceuticals (PMVP) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It details recent filings such as an 8-K report from August 2025 and several Form 4 insider transaction disclosures from July 2025, which i

Tone

Neutral 50/100

Event

Market update

Published

14 Jun 2026 23:40

Source

Stock Titan

PMV Pharmaceuticals Stock (US7301281085): Quiet session puts fundamentals and balance sheet in focus

PMV Pharmaceuticals (PMVP) is experiencing a quiet trading session, bringing focus to its fundamentals, clinical pipeline, and cash position. As a clinical-stage oncology company, its valuation is currently based on its lead p53-targeted program, discovery platform, and balance s

Tone

Neutral 50/100

Event

Balance sheet

Published

12 Jun 2026 15:39

Source

AD HOC NEWS

PMV Pharmaceuticals (PMVP) director receives 42,000 stock options at $1.1900

PMV Pharmaceuticals director Arnold J. Levine was granted 42,000 stock options at an exercise price of $1.1900 per share, as reported in a Form 4 SEC filing. These options are set to expire on June 4, 2036, and will vest on the earlier of June 4, 2027, or the company's next annua

Tone

Neutral 50/100

Event

Market update

Published

06 Jun 2026 08:10

Source

Stock Titan

PMV Pharmaceuticals (PMVP) director awarded 42,000 stock options at $1.19

PMV Pharmaceuticals director Kirsten Flowers was granted 42,000 stock options with an exercise price of $1.19 per share, expiring on June 4, 2036. These options will vest on the earlier of June 4, 2027, or the company's next annual stockholder meeting. This insider transaction in

Tone

Neutral 50/100

Event

Market update

Published

06 Jun 2026 06:10

Source

Stock Titan

PMV Pharmaceuticals (PMVP) director gifts 84K stock options to trust

PMV Pharmaceuticals director Carol Giltner Gallagher recently reported that she received a stock option grant for 42,000 shares and transferred options covering a total of 84,000 shares as bona fide gifts, primarily to The Gallagher Revocable Trust. These transactions were non-ma

Tone

Neutral 50/100

Event

Market update

Published

05 Jun 2026 20:40

Source

Stock Titan

PMV Pharmaceuticals (PMVP) grants director 42,000 options at $1.19

PMV Pharmaceuticals director Laurie Stelzer was granted 42,000 stock options with an exercise price of $1.19 per share, expiring on June 4, 2036. These options will vest on the earlier of June 4, 2027, or the date of the company's next annual stockholder meeting. This transaction

Tone

Neutral 50/100

Event

Market update

Published

05 Jun 2026 20:40

Source

Stock Titan

Director at PMV Pharmaceuticals (PMVP) granted 42,000 options at $1.19

PMV Pharmaceuticals director Charles M. Baum was granted 42,000 stock options with an exercise price of $1.19 per share, expiring on June 4, 2036. The options will vest on the earlier of June 4, 2027, or the company's next annual stockholder meeting. Following this transaction, M

Tone

Neutral 50/100

Event

Market update

Published

05 Jun 2026 20:40

Source

Stock Titan

PMV Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results

PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) announced the results of its 2026 Annual Meeting of Stockholders held virtually on June 4, 2026. Key outcomes included the election of two Class III Directors, David H. Mack, Ph.D. and Laurie Stelzer, and a non-binding advisory approval of

Tone

Neutral 50/100

Event

Earnings

Published

05 Jun 2026 14:04

Source

Minichart

Shareholders back PMV Pharmaceuticals (NASDAQ: PMVP) board, pay plans

PMV Pharmaceuticals (NASDAQ: PMVP) shareholders at their 2026 annual meeting elected David H. Mack, Ph.D. and Laurie Stelzer as Class III directors to serve until the 2029 annual meeting. They also approved, on a non-binding advisory basis, the compensation for named executive of

Tone

Neutral 50/100

Event

Market update

Published

05 Jun 2026 12:39

Source

Stock Titan

Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity

PMV Pharmaceuticals, Inc. (PMVP) shows positive clinical trial activity for rezatapopt in cancer treatment, prompting Oppenheimer to maintain an Outperform rating despite a reduced price target. Although the company has sufficient cash for operations through Q1 2027 for NDA submi

Tone

Neutral 50/100

Event

Analyst action

Published

02 Jun 2026 16:10

Source

Insider Monkey